DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company, has reported its financial results for the three months ended 30 June 2020, it was reported on Monday.

The company reported total revenues at USD25.8m for the three months ended 30 June 2020, compared to total revenues of USD4m in the year-ago period.

The firm posted net income of USD14.3m for the three months ended 30 June 2020, against net loss of USD7.2m in the same period in 2019.

James E Brown, DVM, president and CEO of DURECT, said, 'We continued to make progress in our clinical programs investigating DUR-928, our lead epigenetic regulator, during the second quarter. We were pleased to report positive topline data from our Phase 1b NASH trial and we look forward to presenting additional data from the trial at a future scientific meeting.'